Hypothesis

Age-related loss of gut bacteria that produce indole-3-propionic acid (IPA) diminishes activation of the aryl hydrocarbon receptor (AhR) in brain endothelial cells, lowering claudin‑5 expression and increasing blood‑brain barrier (BBB) permeability. This leaky milieu exacerbates neuroinflammation and creates a hostile environment that limits the survival and integration of transplanted iPSC‑derived neurons. We predict that restoring microbial IPA production—or administering exogenous IPA—will reactivate AhR signaling, tighten the BBB, reduce cytokine influx, and thereby create a permissive niche for iPSC‑based neural grafts in aged hosts.

Mechanistic rationale

• IPA is a tryptophan metabolite generated by specific commensals (e.g., Clostridium sporogenes) and acts as a high‑affinity AhR ligand [1].
• AhR activation in endothelial cells upregulates tight‑junction proteins, notably claudin‑5 and occludin, decreasing paracellular flux [2].
• A tighter BBB limits entry of pro‑inflammatory metabolites such as 3‑hydroxyoctanoic acid and endotoxin, which otherwise activate microglia and impair microglial support of engrafted cells [3].
• Reduced microglial activation shifts the phenotype toward a pro‑repair state, enhancing secretion of neurotrophic factors that support iPSC‑derived neuron maturation and synaptic integration [4].

Testable predictions

1. Microbiota manipulation: Aged mice colonized with an IPA‑producing strain will show higher fecal IPA levels, increased brain endothelial AhR target gene expression, and elevated claudin‑5 immunostaining compared with germ‑aged controls.
2. Pharmacologic rescue: Oral IPA supplementation in aged mice will replicate the microbiota effect, decreasing plasma‑brain efflux of fluorescein‑isothiocyanate‑dextran and lowering cortical IL‑1β and TNF‑α levels.
3. Engraftment outcome: Transplantation of iPSC‑derived dopaminergic neurons into IPA‑treated aged hosts will yield greater graft volume, higher TH‑positive neuron survival, and increased host‑graft synaptogenesis (synapsin‑1 colocalization) than transplants into untreated aged mice.
4. Behavioral rescue: Improved motor performance on the rotarod and pole‑test will correlate with graft integrity only in the IPA‑treated group.
5. Falsifiability: If BBB tightness, microglial phenotype, or graft survival do not improve despite confirmed IPA elevation, the hypothesis is refuted.

Experimental outline

• Use 20‑month‑old C57BL/6 mice; assign to four groups: (a) vehicle control, (b) IPA‑producing probiotic, (c) IPA oral gavage, (d) IPA + AhR antagonist (to test pathway specificity).
• Measure fecal IPA by LC‑MS, brain endothelial AhR‑Cyp1a1 mRNA, claudin‑5 by Western blot/immunofluorescence, BBB permeability via fluorescein‑isothiocyanate‑dextran assay, microglial Iba1/CD86 vs Arg1 staining.
• Two weeks later stereotactically transplant iPSC‑derived DA neurons (validated TH+/FOXA2+).
• At 4 weeks post‑transplant assess graft volume, TH+ cell count, synapsin‑1 overlap, and conduct behavioral tests.

Expected impact

Confirming that a single microbial metabolite can re‑establish a youthful BBB environment would provide a mechanistic bridge between gut‑brain axis modulation and regenerative neurology, offering a pre‑conditioning strategy that could make iPSC therapies viable in aged patients.